Symmetry Medical (SMA)
Q1 2010 Earnings Call
May 06, 2010 05:00 am ET
Carol Ruth - IR, The Ruth Group
Brian Moore - President, CEO and Director
Fred Hite - SVP, CFO and IR Officer
Matt Miksic - Piper Jaffray
James Sidoti - Sidoti
Michael Matson - Wells Fargo Securities
Operator: Good day ladies and gentlemen and welcome to the first quarter 2010 Symmetry Medical Incorporated earnings conference call. My name is Michael and I will be your coordinator for today. At this time all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of this conference. [Operator Instructions]. As a reminder this call is being recorded for replay purposes.
I would now like to turn the presentation over to your host for today's conference Ms. Carol Ruth of the Ruth Group. You may proceed.
Thank you operator. Joining us on the call are Brian Moore, President and Chief Executive Officer and Fred Hite, Senior Vice President and Chief Financial Officer.
Statements made in this conference call regarding Symmetry Medical business which are not historical facts may be forward-looking statements that involve risks and uncertainties within the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are non-frequently identified by the use of terms such as may, will, should, expect, believe, anticipate, plan, may intend and similar words indicating possible future expectations, events or actions.
Such predicative statements are not guarantees of future performance and actual results and outcomes could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to, the loss of one or more customers, the development of new products or product innovation by our competitors, product liability, changes in management, changes in conditions affecting the economy, orthopedic device manufacturers, or the medical device industry in general and changes in government regulation of medical devices and third party reimbursement practices.